Arcus Biosciences (RCUS +5.97%), a clinical-stage biotech focused on cancer immunotherapies, reported its second-quarter 2025 earnings on August 6, 2025. GAAP revenue and earnings per share both surpassed Wall Street expectations by a wide margin, with reported GAAP revenue at $160 million versus consensus estimates of $33.2 million. This beat was almost entirely due to a non-recurring $143 million GAAP revenue recognition tied to Gilead returning rights to one of Arcus’s late-stage drug programs. Earnings per share (GAAP) were break-even ($0.00) compared to an expected GAAP loss of $1.13 per share. Overall, the quarter featured an unusually large headline GAAP beat, continuing progress in its clinical pipeline, and steady financial resources to fund its research priorities.
| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change |
|---|---|---|---|---|
| EPS (GAAP) | $0.00 | ($1.13) | ($1.02) | N/A |
| Revenue (GAAP) | $160 million | $33.2 million | $39 million | 310.3 % |
| Research & Development Expenses | $139 million | $115 million | 20.9 % | |
| General & Administrative Expenses | $29 million | $30 million | -3.3 % | |
| Cash, Cash Equivalents & Marketable Securities (Quarter-end) | $927 million | N/A | N/A |
Source: Analyst estimates for the quarter provided by FactSet.
Business Overview and Corporate Priorities
Arcus Biosciences aims to develop therapies that harness the immune system to fight cancer. Its research focuses on several new drug candidates that may improve outcomes for patients with cancers like kidney, pancreatic, lung, and gastric cancers. The company’s main business revolves around clinical trials on molecules that target different immune pathways, including anti-TIGIT antibodies, HIF-2α inhibitors, CD73 inhibitors, and A2a/A2b adenosine receptor antagonists.
To advance this work, Arcus prioritizes moving late-stage clinical programs toward regulatory approval. Its most advanced asset is casdatifan, a HIF-2α inhibitor being studied for clear cell renal cell carcinoma, a type of kidney cancer. Arcus’s strategy also depends on partnerships with larger pharma companies—especially Gilead Sciences and AstraZeneca—for development funding, collaboration on clinical studies, and commercial reach. The success of the pipeline, maintaining strong partnerships, and prudent financial management remain central to Arcus’s long-term goals.
Significant Developments in the Quarter
Arcus’s headline GAAP financial result for Q2 2025 was heavily shaped by a one-off event. The company recognized $143 million in GAAP catch-up revenue after Gilead Sciences returned rights to etrumadenant, an adenosine receptor antagonist once considered a key pipeline asset. This revenue recognition propelled GAAP revenue far above both last year’s quarter and analyst expectations. However, the underlying business saw little change in ongoing revenue from other operations compared to previous periods.
Arcus increased its GAAP research and development spending to $139 million, up 20.9% from $115 million in Q2 2024. This increase reflected higher chemistry, manufacturing, and controls (CMC) costs and increased early-stage development activities, including Phase 2 activities for casdatifan. Arcus stated it expects these expenses to remain elevated through Q3 2025, then decline as late-stage clinical trials complete enrollment. General and administrative costs decreased from $30 million in Q2 2024 to $29 million.
The company continued to advance its pipeline of candidate drugs. During the quarter, it highlighted progress in several late-stage trials:
Casdatifan, a small-molecule HIF-2α inhibitor for clear cell renal cell carcinoma, began a pivotal Phase 3 clinical trial (PEAK-1) in 2025, comparing its combination with cabozantinib (a tyrosine kinase inhibitor) to cabozantinib alone. Interim combination data as of the March 14, 2025 cutoff showed a confirmed overall response rate (the percentage of patients with tumor shrinkage) of 46% and a favorable safety profile.
In the anti-TIGIT antibody class, the company is running multiple Phase 3 studies in both lung and gastrointestinal cancers. The lead candidate, domvanalimab (an Fc-silent antibody), in combination with zimberelimab (an anti-PD-1 antibody) and chemotherapy, is being studied in the STAR-221 trial for first-line treatment of upper gastrointestinal adenocarcinomas, including gastric cancer, with overall survival data for the Phase 3 STAR-221 study expected in 2026. A separate Phase 2 study, EDGE-Gastric, will present new data in October 2025.
Quemliclustat, a CD73 inhibitor (another immunotherapy approach), received orphan drug status for pancreatic cancer and is enrolling rapidly in a Phase 3 trial (PRISM-1) for metastatic disease.
Following the decision to discontinue development of etrumadenant, Arcus regained full rights to the molecule in June 2025. The associated $143 million GAAP revenue recognized is not expected to repeat in future quarters.
Arcus’s collaborations remain important. Although its partnership with Gilead narrowed with the return of etrumadenant, Gilead continues to support other programs. AstraZeneca now sponsors and operationalizes a new first-line kidney cancer trial (eVOLVE-RCC02, a Phase 1b/3 study in first-line metastatic clear cell renal cell carcinoma).
On the balance sheet, Arcus ended the quarter with $927 million in cash and marketable securities. The company drew on a credit facility and raised additional equity earlier in the year, keeping its liquidity position strong. Net income (GAAP) was roughly break-even, a major improvement from the prior year’s $93 million net loss. The increase in GAAP revenue was driven by a one-time $143 million revenue recognition.
No dividends were declared or changed, as the company continues to reinvest in research and development. RCUS does not currently pay a dividend.
Clinical Pipeline and Product Updates
Arcus’s pipeline is diverse but centers on programs with significant potential in cancer care. Early results suggest superiority in early-phase studies. The PEAK-1 trial combining casdatifan with cabozantinib is a Phase 3 study designed to support regulatory approval. Additional studies, including those with AstraZeneca’s volrustomig (a bispecific antibody that targets two immune checkpoints), aim to enable TKI-free (non-tyrosine kinase inhibitor) treatments, which may reduce side effects for patients.
For gastrointestinal cancers, domvanalimab is Arcus’s lead anti-TIGIT antibody. Its main trial, STAR-221, tests a combination with chemotherapy and zimberelimab versus standard care in first-line gastric, gastroesophageal junction, and esophageal adenocarcinomas. Top-line results are expected next year, with related Phase 2 overall survival results from the EDGE-Gastric study (domvanalimab plus zimberelimab and chemotherapy in upper GI adenocarcinomas) to be presented at the 2025 ESMO Congress in October.
Quemliclustat, the company’s CD73 inhibitor, is being studied in PRISM-1, a randomized Phase 3 trial enrolling newly diagnosed pancreatic ductal adenocarcinoma patients, with enrollment completion expected in Q3 2025. Enrollment is projected to complete by the end of the third quarter, ahead of original plans.
Other pipeline activity includes early-stage programs in small-molecule and immunology research. Arcus’s strategy is to allocate more resources to late-stage clinical programs while maintaining a “lean” early-stage development effort, balancing risk and opportunity.
Outlook and What to Watch in the Next Quarters
Arcus issued updated full-year GAAP revenue guidance of $225 million to $235 million for FY2025, reflecting the impact of the non-recurring revenue event. This range is up from earlier projections of $75 million to $90 million. Management stated it expects research and development costs to peak in 2025 and then begin to decline from Q4 2025 as large late-stage trials like domvanalimab’s close enrollment.
Leadership did not provide further detailed financial guidance for subsequent quarters or years. The cash position as of quarter-end is projected to be sufficient to fund operations through upcoming pivotal clinical trial readouts for casdatifan, domvanalimab, and quemliclustat. As a development-stage company with no approved products, Arcus’s future depends on the success of major upcoming clinical results and regulatory submissions.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
